Dextromethorphan
Tóm tắt
Dextromethorphan is a highly effective and widely used nonopioid antitussive drug. As it has been in use for more than 30 years, a large body of clinical experience has been used to formulate a safety profile. An anthology of adverse drug events has been analysed, drawn both from published case records and a data base recording dextromethorphan-related adverse events spontaneously reported by physicians or pharmacists. The resulting safety profile indicates that adverse drug reactions are infrequent and usually not severe. The predominant symptoms are usually dose related and include neurological, cardiovascular and gastrointestinal disturbances. Particular safety concerns arise when monoamine oxidase inhibiting (MAOI) drugs and dextromethorphan are coadministered. In addition to adverse drug reactions, the safety profile of dextromethorphan is affected by episodic and sporadic abuse. In fact, abuse appeared to be the most significant hazard identified by analysis of spontaneous adverse event reporting. No evidence could be found that the well documented pharmacokinetic polymorphism observed with dextromethorphan is correlated with any clinically significant safety risk if it is used for short term treatment. In summary, the safety profile of dextromethorphan is reassuring, particularly relating to overdose in adults and children.
Tài liệu tham khảo
Bazire S. MAOIs and narcotic analgesics. British Journal of Psychiatry 151: 701–701, 1987
Bickerman HA. Antitussive drugs. In Modell W (Ed.) Drugs of Choice 1984–1985, pp. 483–499, CV Mosby Company, St Louis, 1984
Boeckx RL. False positive EMIT® D.A.U. phencyclidine assay as a result of an overdose of dextromethorphan. Clinical Chemistry 33: 974–975, 1987
Bornstein S, Czermak M, Postel J. A propos a case of voluntary drug poisoning with dextromethorphan hydrobromide. Annals of Medical Psychology 1: 447–451, 1968
Brosen K, Gram LF. Clinical significance of the sparteine/debri-soquine oxidation polymorphism. European Journal of Clinical Pharmacology 36: 537–547, 1989
Browne B, Unter S. Monoamine oxidase inhibitors and narcotic analgesics. British Journal of Psychiatry 151: 210–212, 1987
Chen ZR, Somogyi A, Bochner F. Dextromethorphan: pharmacogenetics, and a pilot study to determine its disposition and antitussive effect in poor and extensive metabolisers. European Journal of Clinical Pharmacology 183: 1573–1574, 1990a
Chen ZR, Somogyi A, Bochner F. Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man. Therapeutic Drug Monitoring 12: 97–104, 1990b
Choi DW. Dextrorphan and dextromethorphan attenuate glutamate neurotoxicity. Brain Research 403: 333–336, 1987
Eddy NB. The National Research Council involvement in the opiate problem: 1928–1971. National Academy of Sciences, Washington, D.C. 1973
Eichelbaum M. Genetic polymorphism of sparteine-debrisoquine oxidation. ISI Atlas of Science, pp. 243–251, ISI Press, Philadelphia, 1988
Engbar TM, Chase TN. Dextromethorphan does not protect against quinolinic acid neurotoxicity in rat striatum. Neuroscience Letters 95: 269–274, 1988
Federal Register 484: 203, 1983
Fleming PM. Dependence on dextromethorphan hydrobromide. British Medical Journal 293: 597, 1986
Guess HA. Limitations of available data on prescription drug safety. In Horisberger B & Dinkel R (Eds) The perception and management of drug safety risks, pp. 52–53, Springer-Verlag, New York, 1989
Harrison WM, McGrath PJ, Stewart JW, Quitkin F. MAOIs and hypertensive crises: the role of OTC drugs. Journal of Clinical Psychiatry 50: 64–65, 1989
Henreting F, Cugini D, Durbin D, Kearney V, Voignier B, et al. Dextromethorphan (DM) overdose in children. Veterinary and Human Toxicology 30: 364, 1988
Jasinski DR. Assessment of the abuse potentiality of morphinelike drugs (methods used in man). In Martin WR (Ed.) Drug addiction: I. Handbook of experimental pharmacology, Vol. 45, pp. 197–258, Springer-Verlag, Berlin, 1977
Jasinski DR. Morphine and nonaddicting analgesics: a current perspective. In Beers RF & Basset EG (Eds) Mechanisms of pain and analgesic compounds, Raven Press, New York, 1979
Karttunen P, Tukiainen H, Silvasti M, Kolonen S. Antitussive effect of dextromethorphan and dextromethorphan salbutamol combination in healthy volunteers with artificially induced cough. Respiration 52: 49–53, 1987
Katona B, Mason S, Weir JH. Dextromethorphan danger. New England Journal of Medicine 314: 993, 1986
Kupfer A, Schmid B, Pfaff G. Pharmacogenetics of dextromethorphan o-demethylation in man. Xenobiotica 16: 421–433, 1986
Kupfer A, Schmid B, Prisig R, Pfaff G. Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism. Lancet 2: 517–518, 1984
Martin WR. General problems of drug abuse and drug dependence. In Martin WR (Ed.) Drug addiction I: Handbook of experimental pharmacology, Vol. 45, pp. 3–40, Springer-Verlag, Berlin, 1977
Matthys H, Bleicher B, Bleicher U. Dextromethorphan and codeine: objective assessment of antitussive activity in patients with chronic cough. Journal of International Medical Research 11: 92–100, 1983
McCarthy JP. Some less familiar drugs of abuse. Medical Journal of Australia 20: 1078–1081, 1971
McElwee NE, Veltri JC. Intentional abuse of dextromethorphan (DM) products: 1985 to 1988 statewide data. Veterinary and Human Toxicology 4: 355, 1990
McElwee NE, Veltri JC. Dextromethorphan exposures reported by emergency departments to the drug abuse warning network, 1987–1990. Journal of Clinical and Research Pharmacology 5: 167–168, 1991a
McElwee NE, Veltri JC. Medical examiner reports of dextromethorphan exposures in the drug abuse warning network. Journal of Clinical and Research Pharmacology 5: 167, 1991b
Meyer UA, Zanger UM, Grant D. Genetic polymorphism of drug metabolism. In Tesa B (Ed.) Advances in drug research, Vol. 19, pp. 197–241, Academic Press, London, 1989
Musacchio JM, Klein M, Canoll PD. Dextromethorphan and sigma ligands: common sites but diverse effects. Life Sciences 45: 1721–1732, 1989
Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clinical Pharmacology and Therapy 38: 402–408, 1985
Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244, 1360–1362, 1989
Orrell MW, Campbell PG. Dependence on dextromethorphan hydrobromide. British Medical Journal 293: 1242–1243, 1986
Perault MC, Bouquet S, Bertschy G, Vandel S, Chakroun R, et al. Debrisquine and dextromethorphan phenotyping and anti-depressant treatment. Therapie 46: 1–3, 1991
Pfaff G, Briegel P, Lamprecht I. Inter-individual variation in the metabolism of dextromethorphan. International Journal of Pharmaceutics 14: 173–189, 1983
Prince DA, Feeser HR. Dextromethorphan protects against cerebral infarction in a rat model of hypoxia-ischemia. Neuroscience Letters 85: 291–296, 1988
Rammer L, Holmgren P, Sandler H. Fatal intoxication by dextromethorphan: a report on two cases. Forensic Science International 37: 233–236, 1988
Reynolds EF (Ed). Martindale: the extra pharmacopoeia, 29th ed., p. 908, Pharmaceutical Press, London, 1989
Rivers N, Horner B. Possible lethal reaction between Nardil and dextromethorphan. Canadian Medical Association Journal 103: 85, 1970
Schmid B, Bircher J, Prisig R, Kupfer A. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-de-methylation with debrisoquine hydroxylation. Clinical and Pharmacological Therapy 38: 618–624, 1985
Seventeenth Report of WHO Expert Committee on Drug Dependence, Technical Report Service WHO no. 437, 1970
Shamsie SJ, Barriga C. The hazards of use of monoamine oxidase inhibitors in disturbed adolescents. Canadian Medical Association Journal 104: 715, 1971
Shaul WL, Wandell M, Robertson WO. Dextromethorphan toxicity: reversal by Naloxone. Pediatrics 59: 117–119, 1977
Sinclair JB. Dextromethorphan-monoamine oxidase inhibitor interaction in rabbits. Journal of Pharmaceutics and Pharmacology 25: 803–808, 1973
Steinberg GK, Bell T. Clinical dose escalation safety study of the NMDA antagonist dextromethorphan in neurosurgical patients. Stroke 22: 141, 1991
Tortella FC, Pellicano M, Bowery NG. Dextromethorphan and neuromodulation: old drug coughs up new activities. Trends in Pharmacological Sciences 10: 501–507, 1989
Weisand MP, Meard D, Ferney DM. Neuropathology in the re-trosplenal cortex of rats after dextromethorphan administration. Society for Neuroscience Abstracts 16: 1116, 1990
Younes RB. Exhilarant cough remedies. New England Journal of Medicine 280: 391, 1969